Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Analogic (ALOG) Share Price

News articles about Analogic (NASDAQ:ALOG) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Analogic earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 47.4686345475502 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news headlines that may have effected Accern Sentiment’s scoring:

A number of research analysts have recently weighed in on the company. Zacks Investment Research raised Analogic from a “hold” rating to a “buy” rating and set a $93.00 price target on the stock in a research note on Tuesday, October 10th. BidaskClub downgraded Analogic from a “hold” rating to a “sell” rating in a research note on Thursday. Finally, Jefferies Group reissued a “hold” rating and issued a $75.00 price target on shares of Analogic in a research note on Wednesday, September 20th. One research analyst has rated the stock with a sell rating and three have assigned a hold rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $85.33.

Shares of Analogic (ALOG) opened at $86.95 on Friday. Analogic has a 1 year low of $66.00 and a 1 year high of $88.45. The company has a market cap of $1,011.88, a price-to-earnings ratio of 48.24, a P/E/G ratio of 4.14 and a beta of 0.86.

Analogic (NASDAQ:ALOG) last released its quarterly earnings data on Wednesday, December 6th. The medical research company reported $0.75 EPS for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.32. Analogic had a negative net margin of 15.27% and a positive return on equity of 4.27%. The business had revenue of $106.90 million during the quarter, compared to analysts’ expectations of $100.55 million. During the same quarter in the prior year, the company earned $0.43 EPS. The firm’s quarterly revenue was down 11.7% on a year-over-year basis. equities analysts forecast that Analogic will post 2.8 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 15th will be given a $0.10 dividend. This represents a $0.40 dividend on an annualized basis and a dividend yield of 0.46%. The ex-dividend date of this dividend is Thursday, December 14th. Analogic’s dividend payout ratio is currently -6.70%.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Analogic (ALOG) Share Price” was first posted by Stock Observer and is owned by of Stock Observer. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.thestockobserver.com/2017/12/08/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-analogic-alog-share-price.html.

Analogic Company Profile

Analogic Corporation designs, manufactures and commercializes guidance, diagnostic imaging and threat detection technologies. The Company operates through three segments: Medical Imaging, Ultrasound, and Security and Detection. The Company’s Medical Imaging segment provides medical imaging systems and subsystems for computed tomography (CT), magnetic resonance imaging (MRI) and high-resolution digital mammography.

Insider Buying and Selling by Quarter for Analogic (NASDAQ:ALOG)

Receive News & Ratings for Analogic Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Analogic Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply